In a report published Tuesday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating on Salix Pharmaceuticals Ltd. SLXP, and raised the price target from $126.00 to $130.00.
In the report, Sterne Agee noted, “The upcoming FDA Advisory Committee on Relistor (scheduled for June 11-12) and the TARGET 3 clinical trial data on Xifaxan expected in early July provide important near-term catalysts for SLXP. We recommend that investors buy SLXP in front of these events. We are adjusting our 2014/2015 EPS estimates to $6.42/$8.12 from $6.90/$8.58 and raising our price target to $130 from $126.”
Salix Pharmaceuticals Ltd. closed on Friday at $114.18.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in